Jose R. Arribas
Hospital Universitario La Paz
What is this?
Publications 269
#1Alberto M. BorobiaH-Index: 14
#2Antonio J. CarcasH-Index: 15
view all 28 authors...
BACKGROUND Since the confirmation of the first patient infected with SARS-CoV-2 in Spain in January 2020, the epidemic has grown rapidly, with the greatest impact on the Madrid region. This article describes the first 2226 consecutive adult patients with COVID-19 admitted to the La Paz University Hospital in Madrid. METHODS Our cohort included all consecutively admitted patients who were hospitalized and who had a final outcome (death or discharge) in a 1286-bed hospital of Madrid (Spain) from F...
#1Rosa de Miguel (Hospital Universitario La Paz)H-Index: 2
Last. Mónica García-ÁlvarezH-Index: 11
view all 22 authors...
ABSTRACT Background We investigated the efficacy of a switch to dolutegravir plus lamivudine in aviremic individuals without evidence of persistent lamivudine resistance-associated mutations in baseline proviral DNA population sequencing. Methods Open-label, single-arm, 48-week pilot trial. HIV-1 infected adults, naive to integrase inhibitors, with CD4+ above 350 cell/μL and fewer than 50 HIV-1 RNA copies per mL the year prior to study entry switched to dolutegravir plus lamivudine. Participants...
#1Benjamin Jean Gaborit (Hotel Dieu Hospital)
Last. François Raffi (Hotel Dieu Hospital)H-Index: 23
view all 8 authors...
Lancet Infectious Diseases, The - Sous presse. Epreuves corrigees par l'auteur. Disponible en ligne depuis le mardi 21 avril 2020
#1Mathieu Chalouni (French Institute of Health and Medical Research)
Last. Brigitte Autran (UPMC: Pierre-and-Marie-Curie University)H-Index: 52
view all 13 authors...
In 31 participants who started first-line antiretroviral therapy in the NEAT 001/ANRS 143 clinical trial, we found after 96 weeks a statistically significant increase in blood telomere length (TL) of 0.04 (T/S Ratio) (p = 0.03). This increase was positively correlated with both the change in the percentage of CD4+ T-cells and with the decrease of CD38+ molecules on Central Memory CD8+ and negatively correlated with the change in the percentage of CD4+ Effector Memory cells. Increase in TL could ...
#1Juan Carlos Ramos-Ramos (Hospital Universitario La Paz)
#2Fernando Lázaro-Perona (Hospital Universitario La Paz)H-Index: 3
Last. Francisco Arnalich (Hospital Universitario La Paz)H-Index: 29
view all 10 authors...
Background: The major reservoir of carbapenemase-producing Enterobacteriaceae (CPE) is the gastrointestinal tract of colonized patients. Colonization is silent and may last for months, but the risk of infection by CPE in colonized patients is significant. Methods: Eight long-term intestinal carriers of OXA-48-producing Enterobacteriaceae (OXA-PE) were treated during 3 weeks with daily oral lactitol (Emportal((R))), Bifidobacterium bifidum and Lactobacillus acidophilus (Infloran((R))). Weekly sto...
AbstractBackground:The 2-drug regimen dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA <50 copies/mL in treatment-naive adults in the 48-week primary analysis of the GEMINI trials. We present results from the prespecified
1 CitationsSource
#1Pedro CahnH-Index: 41
#2J. Sierra MaderoH-Index: 1
Last. Jörg SieversH-Index: 3
view all 21 authors...
1 CitationsSource
#1Clara Crespillo-Andújar (Hospital Universitario La Paz)H-Index: 2
#2Marta Díaz-Menéndez (Hospital Universitario La Paz)H-Index: 13
view all 26 authors...
Abstract Background From the first Zika virus (ZIKV) description, it has progressively widespread worldwide. We analyzed demographic, clinical, microbiologic and travel-related characteristic from returned patients from a ZIKV endemic country in a referral Tropical Medicine Unit. Method A prospective cohort study performed in a Spanish referral center with the aim of determining the significant factors associated with confirmed Zika virus (ZIKV) infection. Results 817 patients, (56% women, media...
#1Richard T. DaveyH-Index: 55
#2Eduardo Fernández-Cruz (Hospital General Universitario Gregorio Marañón)H-Index: 1
view all 153 authors...
Summary Background Since the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might have clinical benefit for patients with influenza infection, but definitive data do not exist. We aimed to evaluate the safety and efficacy of hIVIG in a randomised controlled trial. Methods This randomised, double-blind, placebo-controlled trial was planned for 45 hospitals in Argenti...
8 CitationsSource
#1Belén Alejos (ISCIII: Carlos III Health Institute)H-Index: 7
Last. Jose R. ArribasH-Index: 48
view all 15 authors...